Cannabinoids, Clinical Trials, Information and Treatment

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

Clinical Trials

Clinical Trials Chronic Pain Cannabinoids Patients

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials

Clinical Trials Pharmaceutical Research and Development Cannabinoids

Epilepsy and MMJ: Exploring the Promising Treatment Benefits

MMJ Recs

NOVEMBER 30, 2023

While traditional treatments like antiepileptic drugs exist, they may not always provide adequate relief for all patients. In recent years, there has been growing interest in exploring alternative treatment options, and one that has gained attention is medical marijuana (MMJ).

Epilepsy

Epilepsy Treatment Patients Strains

CDC Seeks Public Comments Regarding Chronic Pain Management

NORML

APRIL 30, 2020

CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. .”

Chronic Pain

Chronic Pain Clinical Trials Data Patients

Review Paper: Clinical Evidence Lacking in Support of CBD as an Anti-Viral Agent

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD

CBD Clinical Trials Data Treatment

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials

Clinical Trials Pharmaceutical Research and Development Cannabinoids

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research. Visit www.floragrowth.ca

Clinical Trials

Clinical Trials Research and Development Pharmaceutical Events

Survey: Three Of Four Military Veterans Would Consider Using Medical Cannabis

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials

Clinical Trials Chronic Pain Data Treatment

Is Cannabis a Viable Mental Health Treatment Option? Part 3 of 3: Anxiety

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment

Treatment Conditions CBD Clinical Trials

United States Minor Cannabinoids (CBG, CBC, CBN, THCV, CBGA) Markets Report 2021-2028 – ResearchAndMarkets.com

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids

Cannabinoids Clinical Trials Research and Development Supply Chain

Unlocking the Potential of CBD: Exploring The Benefits of CBD in Medical Marijuana

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD

CBD Clinical Trials Chronic Pain Epilepsy

Understanding the Efficacy of Medical Cannabis for Terminal Care

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. This study looked at major cannabinoids such as THC and their accuracy and effectiveness in treating the effects of nausea and vomiting.

Chronic Pain

Chronic Pain Clinical Trials Patients Cannabinoids

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain

Chronic Pain Clinical Trials Research and Development Events

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials

Clinical Trials Research and Development Treatment Therapy

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials

Clinical Trials Research and Development Therapy Policy

Using Cannabis to Treat Glaucoma

Medicinal Marijuana Association

FEBRUARY 11, 2024

The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community. Potential for enhanced treatment outcomes with cannabis use. Improves optic nerve blood flow and protects retinal cells.

Treatment

Treatment Blood Pressure Conditions Clinical Trials

Flora Growth Announces Patent-Pending Cannabinoid-Based Product, Seeks INVIMA (Colombian FDA) Emergency Use Authorization Under COVID-19 Protocols

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids

Cannabinoids Clinical Trials Events Cultivation

Cannabis and OCD: Seeking Relief

PrestoDoctor

SEPTEMBER 15, 2023

While there are a variety of treatments available, many individuals do not find relief with traditional medications or therapies. It is a serious medical condition that requires appropriate treatment and support. Furthermore, conventional treatments often focus on symptom management rather than addressing the root causes of OCD.

Research and Development

Research and Development Therapy Treatment Strains

What is CBN (Cannabinol)? How does the natural byproduct of THC work?

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinical trials tell us?

THC

THC Sleep Clinical Trials Cannabinoids

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. More than 8 percent of those surveyed also reported already using cannabinoids, with 54 percent noting a beneficial clinical effect.

Patients

Patients Clinical Trials Research and Development Treatment

Study: Cannabinoids Effective for Post Traumatic Stress Patients

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS). Full Abstract.

Cannabinoids

Cannabinoids Patients Clinical Trials Research and Development

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety

Safety Cannabinoids Events Data

Realm of Caring Appoints Research Director to Oversee Groundbreaking Cannabis Data Registry and Medical Studies

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., Research opportunities such as the ORR expand the existing scientific knowledge base to better inform clinical decision making, and also dispels the stigma surrounding medicinal cannabis use.”.

Data

Data Epilepsy Research and Development Clinical Trials

CBD Science Update

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD

CBD Blood Pressure Research and Development Cannabinoids

Why more Parkinson’s patients don’t use cannabis

The Cannigma

MARCH 18, 2021

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated. Where do Parkinson’s patients get information about cannabis? Here are the most interesting statistics from the survey.

Patients

Patients Clinical Trials Treatment Cannabis

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development

Research and Development Clinical Trials Events Cannabinoids

Press Release: MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

Cannabis Law Report

AUGUST 10, 2022

The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. BARRIE, ON , Aug. 9, 2022 /CNW/ – MediPharm Labs Corp. MediPharm Labs Corp.

Clinical Trials

Clinical Trials Medicine Pharmaceutical THC

More than half of prescriptions for medicinal cannabis in Australia given in Queensland, study says

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes. of prescriptions were for sleep disorders. Read their full article at.

Medicine

Medicine Clinical Trials Data Sleep

Marijuana Could Reduce Brain Damage After Stroke, Researchers Say

Otherside Farms

JANUARY 25, 2019

Scientists hope to perform human trials in the near future. Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes.

Clinical Trials

Clinical Trials Marijuana Cannabinoids Data

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development

Research and Development Clinical Trials Consumption Patients

CBD Science Update

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD

CBD Blood Pressure Research and Development Cannabinoids

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For more information visit: [link]. Orphan Drug Designation? 561-627-9455.

DEA

DEA Clinical Trials THC Research and Development

These Patient Advocacy Groups Are Working Together to Expand the Scope of Cannabis Research

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. The ORR, an ongoing online survey study, collects self-reported health information to be analyzed by Johns Hopkins for published research papers.

Advocacy

Advocacy Patients Clinical Trials Education

Press Release: EMMAC and Imperial College London manuscript to be published in peer-reviewed Cannabis and Cannabinoid Research Journal

Cannabis Law Report

JULY 4, 2019

The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry.

Cannabinoids

Cannabinoids Clinical Trials Chronic Pain Medicine

Breaking the Stigma: Shifting Attitudes Toward Medical Marijuana Nationwide

MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. This prompted some states to take the first steps toward legalizing medical marijuana.

Marijuana

Marijuana Chronic Pain Advocacy Research and Development

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients

Patients Education Marijuana Therapy

IMPORTANT HEALTH MESSAGE: Don’t mix THC with COVID-19, Aurelius researchers say

Cannabis Law Report

MARCH 22, 2020

Aurelius Data, a company dedicated to providing data around plant-based medicines, warned the public Tuesday that THC and COVID-19 don’t mix, based on what they know about how cannabinoids affect patients with influenza. A: Based on currently available information, WHO does not recommend against the use of of ibuprofen.

THC

THC Clinical Trials Data Consumption

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical

Pharmaceutical Clinical Trials Research and Development Programs

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials

Clinical Trials Research and Development Therapy Conditions

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

APRIL 11, 2022

We could potentially develop north of 11,000 drugs that are cannabinoid-based. In particular, of all the components contained in the cannabis plant— including cannabinoids , terpenes , and flavonoids — the cannabis compound tetrahydrocannabinol (THC) has proven to harbor medicinal benefits when used in specific formulations.

Pharmaceutical

Pharmaceutical Research and Development DEA Clinical Trials

6 Myths About CBD Products You Should Debunk

Cannabis Law Report

DECEMBER 28, 2021

This is all thanks to CBD, or cannabidiol, one of the most important cannabinoids identified in cannabis plants. But what makes CBD different from other cannabinoids is its therapeutic properties. This is because Epidiolex has been proven an effective treatment after going through various clinical trials.

CBD

CBD Clinical Trials Consumption Chronic Pain

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

Cannabis Law Report

MARCH 25, 2020

. “It is very exciting to announce that Sapphire Biotech has both a diagnostic application as well as a promising oncology treatment in their arsenal. This acquisition marks a transformation of AXIM while aligning with the therapeutic cannabinoid analog space.” For more information, please visit www.AXIMBiotech.com.

Research and Development

Research and Development Supply Chain Pharmaceutical Clinical Trials

Sleepless Nights and CBD

LifeCannMD

AUGUST 23, 2021

CBD is an increasingly popular alternative to traditional sleep medications and treatments. CBD is a common cannabinoid that does not have psychoactive properties as it does not contain THC. Most clinical trials have involved doses between 25 to 1,500 mg. CBD also doesn’t lead to any potential dependence or abuse.

CBD

CBD Sleep Clinical Trials Cannabinoids

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development

Research and Development DEA Clinical Trials Therapy

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Trending Sources

Epilepsy and MMJ: Exploring the Promising Treatment Benefits

CDC Seeks Public Comments Regarding Chronic Pain Management

Review Paper: Clinical Evidence Lacking in Support of CBD as an Anti-Viral Agent

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Survey: Three Of Four Military Veterans Would Consider Using Medical Cannabis

Is Cannabis a Viable Mental Health Treatment Option? Part 3 of 3: Anxiety

United States Minor Cannabinoids (CBG, CBC, CBN, THCV, CBGA) Markets Report 2021-2028 – ResearchAndMarkets.com

Unlocking the Potential of CBD: Exploring The Benefits of CBD in Medical Marijuana

Understanding the Efficacy of Medical Cannabis for Terminal Care

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Using Cannabis to Treat Glaucoma

Flora Growth Announces Patent-Pending Cannabinoid-Based Product, Seeks INVIMA (Colombian FDA) Emergency Use Authorization Under COVID-19 Protocols

Cannabis and OCD: Seeking Relief

What is CBN (Cannabinol)? How does the natural byproduct of THC work?

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

Study: Cannabinoids Effective for Post Traumatic Stress Patients

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Realm of Caring Appoints Research Director to Oversee Groundbreaking Cannabis Data Registry and Medical Studies

CBD Science Update

Why more Parkinson’s patients don’t use cannabis

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Press Release: MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

More than half of prescriptions for medicinal cannabis in Australia given in Queensland, study says

Marijuana Could Reduce Brain Damage After Stroke, Researchers Say

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

CBD Science Update

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

These Patient Advocacy Groups Are Working Together to Expand the Scope of Cannabis Research

Press Release: EMMAC and Imperial College London manuscript to be published in peer-reviewed Cannabis and Cannabinoid Research Journal

Breaking the Stigma: Shifting Attitudes Toward Medical Marijuana Nationwide

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

IMPORTANT HEALTH MESSAGE: Don’t mix THC with COVID-19, Aurelius researchers say

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

6 Myths About CBD Products You Should Debunk

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

Sleepless Nights and CBD

Senators Call For Report On State Of Psychedelic Research

Stay Connected